Why Lantheus Holdings (LNTH) Stock Is Down 4%
Lantheus shares are trading lower by 5.4% during Monday's session. The company announced a $350 million acquisition.
Lantheus To Buy Neuraceq Owner Life Molecular Imaging For Upfront Payment Of $350 Mln
Lantheus Holdings Inc. (LNTH), a radiopharmaceutical-focused company, announced Monday a definitive agreement to acquire Life ...
Nasdaq14d
Lantheus To Buy Neuraceq Owner Life Molecular Imaging For Upfront Payment Of $350 Mln
Brian Markison, CEO of Lantheus, said the acquisition aligns with its strategy to drive long-term growth and value creation by investing in high-potential, complementary assets and R&D ...
northeast.newschannelnebraska16d
Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement
We look forward to continuing this positive momentum going forward.” Lantheus CEO Brian Markison said: “We are pleased to increase our holding in Radiopharm, while continuing to work jointly in ...
The Daily Telegraph16d
Health Check: Radiopharm dials up after gaining new major shareholder
Lantheus CEO Brian Markison said the company was pleased to increase its holding in Radiopharm, while continuing to work jointly in Australia on the clinical development of radiopharmaceutical assets.
Motley Fool Australia16d
2 ASX small-cap shares rocketing 35% to 54% today
Lantheus CEO Brian Markison added, "We are pleased to increase our holding in Radiopharm, while continuing to work jointly in Australia on the clinical development of radiopharmaceutical assets." ...